Company Replimune Group, Inc.

Equities

REPL

US76029N1063

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:26:14 2024-03-28 pm EDT 5-day change 1st Jan Change
8.265 USD +0.18% Intraday chart for Replimune Group, Inc. +0.61% -2.14%

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the business of oncolytic immunotherapy to treat cancer patients. The Company is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The Company's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The Company's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.

Number of employees: 284

Managers

Managers TitleAgeSince
Founder 66 15-02-28
Founder 52 15-02-28
Founder 59 15-02-28
Director of Finance/CFO 44 23-09-18
Chief Tech/Sci/R&D Officer 58 22-11-30
Corporate Officer/Principal 53 21-05-09
Comptroller/Controller/Auditor 48 20-07-31
Corporate Officer/Principal 56 23-01-02
Corporate Officer/Principal 53 21-05-02
Corporate Officer/Principal 50 15-10-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 63 20-03-31
Director/Board Member 59 17-09-30
Founder 59 15-02-28
Founder 52 15-02-28
Director/Board Member 66 18-04-30
Director/Board Member 64 17-06-30
Director/Board Member 54 21-11-30
Chairman 63 18-06-21
Director/Board Member 52 23-05-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 61,387,786 56,875,445 ( 92.65 %) 0 92.65 %

Shareholders

NameEquities%Valuation
Baker Bros. Advisors LP
15.55 %
9,545,336 15.55 % 82 M $
T. Rowe Price International Ltd.
9.528 %
5,849,251 9.528 % 50 M $
5,111,521 8.327 % 44 M $
Forbion Capital Partners Management Holding BV
7.927 %
4,866,499 7.927 % 42 M $
Morgan Stanley Investment Management, Inc.
7.244 %
4,447,228 7.244 % 38 M $
BlackRock Advisors LLC
7.026 %
4,312,939 7.026 % 37 M $
Redmile Group LLC
6.296 %
3,865,258 6.296 % 33 M $
Omega Fund Management LLC
4.889 %
3,001,319 4.889 % 26 M $
Vanguard Fiduciary Trust Co.
4.460 %
2,737,773 4.460 % 23 M $
Goldman Sachs Asset Management LP
3.647 %
2,238,883 3.647 % 19 M $

Company contact information

Replimune Group, Inc.

500 Unicorn Park Drive Suite 303

01801, Woburn

+781 222 9600

http://www.replimune.com
address Replimune Group, Inc.(REPL)